Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MPO | P05164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238581 | 0.80 | MAPK9 (0.43) | NCF1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL4989870 | 0.79 | CYP3A4 (0.41) | PDE5AEGFRFGFR1SRCABL1 | |
| SCHEMBL29576688 | 0.79 | LMNA (0.44) | NR4A2SOS2PDE5AEGFRFGFR1 | |
| SCHEMBL241568 | 0.79 | LMNA (0.44) | NR4A2SOS2PDE5AEGFRFGFR1 | |
| SCHEMBL12978384 | 0.79 | ALDH1A1 (0.43) | PDE5AEGFRFGFR1SRCABL1 | |
| SCHEMBL11772709 | 0.79 | EGFR (0.45) | PDE5AEGFRFGFR1SRCABL1 | |
| SCHEMBL11769755 | 0.79 | PDE5A (0.40) | PDE5AEGFRFGFR1SRCABL1 | |
| SCHEMBL12978382 | 0.75 | CCR1 (0.44) | PDE5AEGFRFGFR1SRCABL1 | |
| SCHEMBL13163277 | 0.73 | LMNA (0.49) | KDM4EALDH1A1POLBLMNAMAPT | |
| SCHEMBL4986913 | 0.73 | HASPIN (0.46) | PDE5AEGFRFGFR1SRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371259-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-12-18 | — | — | US | claimed |
| WO-2013116228-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/ REDOX FACTOR-1 (HAPE1) ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-08-08 | — | — | WO | claimed |
| US-9624235-B2 | Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624235-B2 | Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140371259-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371259-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2809672-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013116228-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/ REDOX FACTOR-1 (HAPE1) ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013116228-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/ REDOX FACTOR-1 (HAPE1) ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013116382-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1465625-B1 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7517883-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7049315-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060052381-A1 | Solubilized topoisomerase poisons | LAVOIE EDMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1465625-A4 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050009824-A1 | Solubilized topoisomerase poisons | RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE | 2005-01-13 | — | — | US | disclosed |
| EP-1465625-A2 | SOLUBILIZED TOPOISOMERASE POISONS | Rutgers, The State University (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009824-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | NR4A2 4259/4885SOS2 4476/4885NCF1 2138/4885 |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | NR4A2 4259/4885SOS2 4476/4885NCF1 2138/4885 |
| US-20140371259-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY | APEX1, NFE2, FEN1 | NR4A2 1015/4885SOS2 2718/4885NCF1 73/4885 |
| US-20060052381-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | NR4A2 4259/4885SOS2 4476/4885NCF1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.